Laura Langohr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laura Langohr has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Esa Pitkänen
Institute for Molecular Medicine Finland (FIMM), HILIFE, University of Helsinki, Finland
4 shared publications - Jessica Koski
University of Helsinki, Helsinki, Finland
4 shared publications - Marja Hakkarainen
Helsinki University Hospital and University of Helsinki, Helsinki, Finland
4 shared publications - Outi Kilpivaara
Applied Tumor Genomics Research Program, Research Programs Unit, Faculty of Medicine University of Helsinki Helsinki Finland
4 shared publications - Ulla Wartiovaara-Kautto
Applied Tumor Genomics Research Program, Research Programs Unit, Faculty of Medicine University of Helsinki Helsinki Finland
4 shared publications - Caroline A. Heckman
University of Helsinki
3 shared publications
Latest Publications
- Open Access
Intense TP53 pathway selection drives clonal evolution from bone marrow failure to leukemia in ERCC6L2 disease
ERCC6L2 disease (ED) is an inherited bone marrow failure (BMF) syndrome that progresses almost exclusively to erythroid, TP53-mutated myeloid malignancy, but the somatic evolution underlying the progression in patients is unknown. We characterized the genetic landscape of 29 ED patients with longitudinal sampling, integrating whole-genome and single-cell RNA sequencing, and compared the findings with Shwachman-Diamond syndrome (SDS), another TP53 mutation-prone disease, to define somatic evolution across disease stages. ED was defined by early, intense, and recurrent selection of TP53-mutant clones: TP53 mutations were more frequent, more often multiple, and showed steeper age-related expansion than in SDS; all TP53-negative ED patients were children. The burden of multiple TP53 mutations exceeded that of sporadic TP53-mutated myeloid neoplasia and was evident before malignancy. Missense mutations dominated the BMF phase, whereas non-missense mutations were seen in patients with malignancy, consistent with biallelic second hits, marking a stage-dependent shift in p53 inactivation. Beyond TP53, the landscape was strikingly restricted, with PPM1D as the only recurrent driver gene. Notably, despite the DNA-repair function of ERCC6L2, no ED-specific mutational signature emerged; but instead reflected age-associated processes. Malignant progression was accompanied by a complex karyotype, recurrent chromosome 5, 7, and 12p losses enriched in erythroid progenitors, and kataegis, consistent with branched, erythroid-predominant clonal evolution. Our findings establish ED as a paradigm of preleukemic dependency on p53-pathway attenuation. As progression is driven predominantly by p53 and captured longitudinally from the earliest clones, ED offers a model of how TP53-mutated leukemia arises and evolves, with relevance beyond a rare syndrome.
Open AccessIntense TP53 pathway selection drives clonal evolution from bone marrow failure to leukemia in ERCC6L2 disease
ERCC6L2 disease (ED) is an inherited bone marrow failure (BMF) syndrome that progresses almost exclusively to erythroid, TP53-mutated myeloid malignancy, but the somatic evolution underlying the progression in patients is unknown. We characterized the genetic landscape of 29 ED patients with longitudinal sampling, integrating whole-genome and single-cell RNA sequencing, and compared the findings with Shwachman-Diamond syndrome (SDS), another TP53 mutation-prone disease, to define somatic evolution across disease stages. ED was defined by early, intense, and recurrent selection of TP53-mutant clones: TP53 mutations were more frequent, more often multiple, and showed steeper age-related expansion than in SDS; all TP53-negative ED patients were children. The burden of multiple TP53 mutations exceeded that of sporadic TP53-mutated myeloid neoplasia and was evident before malignancy. Missense mutations dominated the BMF phase, whereas non-missense mutations were seen in patients with malignancy, consistent with biallelic second hits, marking a stage-dependent shift in p53 inactivation. Beyond TP53, the landscape was strikingly restricted, with PPM1D as the only recurrent driver gene. Notably, despite the DNA-repair function of ERCC6L2, no ED-specific mutational signature emerged; but instead reflected age-associated processes. Malignant progression was accompanied by a complex karyotype, recurrent chromosome 5, 7, and 12p losses enriched in erythroid progenitors, and kataegis, consistent with branched, erythroid-predominant clonal evolution. Our findings establish ED as a paradigm of preleukemic dependency on p53-pathway attenuation. As progression is driven predominantly by p53 and captured longitudinally from the earliest clones, ED offers a model of how TP53-mutated leukemia arises and evolves, with relevance beyond a rare syndrome.
- Open Access
- 16 June 2026
- Published by Wiley in HemaSphere
- Vol. 10 (6) , e70374
Distinct stem cell identities converge into shared erythroid stress in ERCC6L2 disease and Shwachman–Diamond syndrome
ERCC6L2 disease (ED) is a rare bone marrow failure syndrome caused by biallelic germline mutations in ERCC6L2 . ED leads to the accumulation of somatic TP53 mutations, myelodysplastic syndrome, and acute myeloid leukemia (AML) with erythroid predominance and poor prognosis. While ERCC6L2 is implicated in DNA replication and repair, the transcriptomic events underlying delayed erythropoiesis and leukemic progression remain largely undefined. To delineate these processes, we leverage bulk and single‐cell transcriptomics of patient fibroblasts, bone marrow, and peripheral blood across disease stages, including single‐cell TP53 genotyping. We identify disease‐associated erythroid dysregulation and ferroptotic stress emerging prior to TP53 mutation, highlighting an early vulnerability in ED leukemogenesis. We compare ED to Shwachman–Diamond syndrome (SDS) to reveal shared and disease‐specific transcriptional programs. TP53 mutations in ED and SDS arise in hematopoietic stem and progenitor cells but do not independently drive changes in cell cycle or stress pathways during erythropoiesis, despite harboring distinct germline defects. Both diseases converge in late erythropoiesis into a stress state characterized by ferroptotic signaling, G1 arrest, and BCL2L1 upregulation. As a disease‐specific pattern, ED shows aberrant erythroid priming with TP53 ‐driven differentiation arrest shaping progression toward erythroid leukemia. Thereby, we establish the first patient‐level single‐cell map of ED and provide a curated resource for future work on ED, SDS, and TP53 ‐driven leukemogenesis. Overall, our findings in pre‐malignant ED offer a window into early alterations leading to high‐risk leukemia.
- 16 June 2026
- Published by Wiley in HemaSphere
- Vol. 10 (6) , e70374
Open AccessDistinct stem cell identities converge into shared erythroid stress in ERCC6L2 disease and Shwachman–Diamond syndrome
ERCC6L2 disease (ED) is a rare bone marrow failure syndrome caused by biallelic germline mutations in ERCC6L2 . ED leads to the accumulation of somatic TP53 mutations, myelodysplastic syndrome, and acute myeloid leukemia (AML) with erythroid predominance and poor prognosis. While ERCC6L2 is implicated in DNA replication and repair, the transcriptomic events underlying delayed erythropoiesis and leukemic progression remain largely undefined. To delineate these processes, we leverage bulk and single‐cell transcriptomics of patient fibroblasts, bone marrow, and peripheral blood across disease stages, including single‐cell TP53 genotyping. We identify disease‐associated erythroid dysregulation and ferroptotic stress emerging prior to TP53 mutation, highlighting an early vulnerability in ED leukemogenesis. We compare ED to Shwachman–Diamond syndrome (SDS) to reveal shared and disease‐specific transcriptional programs. TP53 mutations in ED and SDS arise in hematopoietic stem and progenitor cells but do not independently drive changes in cell cycle or stress pathways during erythropoiesis, despite harboring distinct germline defects. Both diseases converge in late erythropoiesis into a stress state characterized by ferroptotic signaling, G1 arrest, and BCL2L1 upregulation. As a disease‐specific pattern, ED shows aberrant erythroid priming with TP53 ‐driven differentiation arrest shaping progression toward erythroid leukemia. Thereby, we establish the first patient‐level single‐cell map of ED and provide a curated resource for future work on ED, SDS, and TP53 ‐driven leukemogenesis. Overall, our findings in pre‐malignant ED offer a window into early alterations leading to high‐risk leukemia.
- Open Access
Distinct Stem Cell Identities Converge into Shared Erythroid Stress in ERCC6L2 Disease and Shwachman-Diamond Syndrome
ERCC6L2 disease (ED) is a rare bone marrow failure syndrome caused by biallelic germline mutations in ERCC6L2 . ED leads to accumulation of somatic TP53 mutations, myelodysplastic syndrome, and acute myeloid leukemia (AML) with erythroid predominance and poor prognosis. Given the global challenge of treating TP53 -mutated AML, ED provides a unique opportunity to study early events leading to high-risk leukemia. While ERCC6L2 is implicated in DNA replication and repair, the transcriptomic events underlying delayed erythropoiesis and leukemic progression remain largely undefined. To delineate these processes, we leverage bulk and single-cell transcriptomics of patient fibroblasts, bone marrow, and peripheral blood across disease stages, including single-cell TP53 genotyping. We identify disease-associated erythroid delay and ferroptotic stress emerging prior to TP53 mutation, highlighting an early vulnerability in ED leukemogenesis. We compare ED to Shwachman-Diamond syndrome (SDS) to reveal shared and disease-specific transcriptional programs. TP53 mutations in ED and SDS arise in hematopoietic stem and progenitor cells but do not independently drive changes in cell cycle or stress pathways during erythropoiesis. Both diseases converge in late erythropoiesis into a stress state characterized by ferroptotic signaling, G1 arrest, and BCL2L1 upregulation. As a disease-specific pattern, ED shows aberrant erythroid priming and a differentiation block in TP53 -mutated cells during leukemic transformation. Taken together, we provide the first single-cell analyses in ED, define stress responses shared with SDS, and aberrant erythroid priming with TP53 -driven differentiation arrest shaping progression toward erythroid leukemia. Our results give biological insights to guide therapy development aiming at intercepting disease evolution to treatment-refractory AML. Key points: ERCC6L2 disease patient cells engage maladaptive erythroid programs early in differentiation Cell cycle and ferroptotic stress signatures persist despite somatic TP53 mutations
Open AccessDistinct Stem Cell Identities Converge into Shared Erythroid Stress in ERCC6L2 Disease and Shwachman-Diamond Syndrome
ERCC6L2 disease (ED) is a rare bone marrow failure syndrome caused by biallelic germline mutations in ERCC6L2 . ED leads to accumulation of somatic TP53 mutations, myelodysplastic syndrome, and acute myeloid leukemia (AML) with erythroid predominance and poor prognosis. Given the global challenge of treating TP53 -mutated AML, ED provides a unique opportunity to study early events leading to high-risk leukemia. While ERCC6L2 is implicated in DNA replication and repair, the transcriptomic events underlying delayed erythropoiesis and leukemic progression remain largely undefined. To delineate these processes, we leverage bulk and single-cell transcriptomics of patient fibroblasts, bone marrow, and peripheral blood across disease stages, including single-cell TP53 genotyping. We identify disease-associated erythroid delay and ferroptotic stress emerging prior to TP53 mutation, highlighting an early vulnerability in ED leukemogenesis. We compare ED to Shwachman-Diamond syndrome (SDS) to reveal shared and disease-specific transcriptional programs. TP53 mutations in ED and SDS arise in hematopoietic stem and progenitor cells but do not independently drive changes in cell cycle or stress pathways during erythropoiesis. Both diseases converge in late erythropoiesis into a stress state characterized by ferroptotic signaling, G1 arrest, and BCL2L1 upregulation. As a disease-specific pattern, ED shows aberrant erythroid priming and a differentiation block in TP53 -mutated cells during leukemic transformation. Taken together, we provide the first single-cell analyses in ED, define stress responses shared with SDS, and aberrant erythroid priming with TP53 -driven differentiation arrest shaping progression toward erythroid leukemia. Our results give biological insights to guide therapy development aiming at intercepting disease evolution to treatment-refractory AML. Key points: ERCC6L2 disease patient cells engage maladaptive erythroid programs early in differentiation Cell cycle and ferroptotic stress signatures persist despite somatic TP53 mutations
- Open Access
Pathogenicity evaluation of coding germline variants identifies rare alleles enriched in hematological patients of a founder population
Background: The clinical significance of most germline variants in hematological malignancies (HMs) remains unknown. This presents a challenge in the clinical setting, as the inability to accurately detect pathogenic variants can influence therapeutic decisions. Population isolates have been shown to be beneficial in pathogenic variant discovery due to presence of rare deleterious variants in relatively high frequencies. Methods: We developed and applied PaVaDi, a computational pipeline that follows American College of Medical Genetics and Genomics (ACMG) guidelines, to evaluate the pathogenicity of germline variants in 511 HM patients from the Finnish founder population. We conducted an exome-wide burden analysis to assess the overall contribution of pathogenic variants to HMs and identified significant gene associations. We also examined genes previously associated with hematological diseases and DNA repair in more detail, and performed protein stability analyses to resolve variants of unknown significance (VUS). Results: The exome-wide burden analysis revealed potential pathogenic alleles in CUX2, RNPC3, and MFSD2A that have not previously been linked to HM predisposition. We also identified the largest series of CHEK2 variant carriers reported in hematological diseases, including pathogenic/likely pathogenic (P/LP) variants ( n =19), Ile200Thr ( i.e. , Ile157Thr) ( n =49), and other variants of uncertain significance ( n =3). CHEK2 variants were 1.7-fold enriched in patients compared to controls (13.9% vs 8.3%, p =2×10 −5 ). Strikingly, Ile200Thr was enriched over four-fold in acute lymphoblastic leukemia patients. Finally, protein structure stability analyses suggested novel MPO variants to be potentially highly deleterious. Conclusions: This study highlights the importance of germline testing in hematological malignancies and demonstrates the utility of population isolates for pathogenic variant discovery. Our findings identify a significant burden of deleterious variants in HM patients, particularly in CHEK2 , and underscore the potential of multi-disease joint analyses in revealing germline contributions to hematological diseases.
Open AccessPathogenicity evaluation of coding germline variants identifies rare alleles enriched in hematological patients of a founder population
Background: The clinical significance of most germline variants in hematological malignancies (HMs) remains unknown. This presents a challenge in the clinical setting, as the inability to accurately detect pathogenic variants can influence therapeutic decisions. Population isolates have been shown to be beneficial in pathogenic variant discovery due to presence of rare deleterious variants in relatively high frequencies. Methods: We developed and applied PaVaDi, a computational pipeline that follows American College of Medical Genetics and Genomics (ACMG) guidelines, to evaluate the pathogenicity of germline variants in 511 HM patients from the Finnish founder population. We conducted an exome-wide burden analysis to assess the overall contribution of pathogenic variants to HMs and identified significant gene associations. We also examined genes previously associated with hematological diseases and DNA repair in more detail, and performed protein stability analyses to resolve variants of unknown significance (VUS). Results: The exome-wide burden analysis revealed potential pathogenic alleles in CUX2, RNPC3, and MFSD2A that have not previously been linked to HM predisposition. We also identified the largest series of CHEK2 variant carriers reported in hematological diseases, including pathogenic/likely pathogenic (P/LP) variants ( n =19), Ile200Thr ( i.e. , Ile157Thr) ( n =49), and other variants of uncertain significance ( n =3). CHEK2 variants were 1.7-fold enriched in patients compared to controls (13.9% vs 8.3%, p =2×10 −5 ). Strikingly, Ile200Thr was enriched over four-fold in acute lymphoblastic leukemia patients. Finally, protein structure stability analyses suggested novel MPO variants to be potentially highly deleterious. Conclusions: This study highlights the importance of germline testing in hematological malignancies and demonstrates the utility of population isolates for pathogenic variant discovery. Our findings identify a significant burden of deleterious variants in HM patients, particularly in CHEK2 , and underscore the potential of multi-disease joint analyses in revealing germline contributions to hematological diseases.